Comparison of Molecular International Prognostic Scoring System (M-IPSS) and Revised International Prognostic Scoring System (R-IPSS) in Thai patients with myelodysplastic neoplasms
Issued Date
2022-01-01
Resource Type
ISSN
10245332
eISSN
16078454
Scopus ID
2-s2.0-85144587452
Pubmed ID
36519260
Journal Title
Hematology (United Kingdom)
Volume
27
Issue
1
Start Page
1294
End Page
1297
Rights Holder(s)
SCOPUS
Bibliographic Citation
Hematology (United Kingdom) Vol.27 No.1 (2022) , 1294-1297
Suggested Citation
Polprasert C. Comparison of Molecular International Prognostic Scoring System (M-IPSS) and Revised International Prognostic Scoring System (R-IPSS) in Thai patients with myelodysplastic neoplasms. Hematology (United Kingdom) Vol.27 No.1 (2022) , 1294-1297. 1297. doi:10.1080/16078454.2022.2156682 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/86226
Title
Comparison of Molecular International Prognostic Scoring System (M-IPSS) and Revised International Prognostic Scoring System (R-IPSS) in Thai patients with myelodysplastic neoplasms
Author(s)
Other Contributor(s)
Abstract
Introduction: Risk stratification is essential for treatment decision in myelodysplastic neoplasms (MDS). Molecular international prognostic scoring system (M-IPSS) has been recently developed combining somatic mutations and clinical information being used in the revised international prognostic scoring system (R-IPSS). Objective: We aimed to explore the performances of M-IPSS and R-IPSS in Thai patients with MDS. Method: MDS patients were stratified into risk categories using R-IPSS and M-IPSS scores. The performance of both models were evaluated for prognostic prediction. Results: One hundred and sixty-two MDS patients were recruited from the multicenter study. Survival analysis revealed that both R-IPSS and M-IPSS were good prediction models with the Concordance Index (C-index) of 0.71 (95% Confidence interval [CI] 0.64–0.78) and 0.75 (95% CI 0.69–0.80), respectively (p = 0.22). Comparing the two, 13 of 162 (8%) cases were re-staged between lower and higher risks which would have affected treatment decisions. Conclusion: Our study showed that R-IPSS score can be used for risk stratification in most Thai patients. A prediction model using somatic mutations specifically in Asian patients should be formulated in the future.